FDA Gives Thumb’s Up for Phase 2 Trial of Izokibep in AS Patients

FDA Gives Thumb’s Up for Phase 2 Trial of Izokibep in AS Patients

286459

FDA Gives Thumb’s Up for Phase 2 Trial of Izokibep in AS Patients

The U.S. Food and Drug Administration (FDA) has cleared the start of a Phase 2 trial of izokibep in people with ankylosing spondylitis (AS), according to the therapy’s developers Affibody AB and Inmagene Biopharmaceuticals. “Obtaining FDA IND [investigational new drug] clearance is an important milestone for the izokibep program,” Jean-Louis Saillot, MD, Inmagene‘s chief development officer, said in a press release. “Working closely with our partner Affibody, the Inmagene team is excited to develop a…

You must be logged in to read/download the full post.